title: Role of treatment for depressive symptoms in relieving the impact of fatigue in HIV-HCV co-infected patients: ANRS Co13 Hepavih, France, 2006-2008.
abstract: Fatigue is a major component of quality of life (QOL) and is associated with depression in HIV-HCV co-infected individuals. We investigated whether treating depressive symptoms (DS) could mitigate the impact of fatigue on daily functioning in co-infected patients, even those at an advanced stage of disease. The analysis was conducted on enrollment data of 328 HIV-HCV co-infected patients recruited in the French nationwide ANRS CO 13 HEPAVIH cohort. Data collection was based on medical records and self-administered questionnaires which included items on socio-behavioural data, the fatigue impact scale (FIS) in three domains (cognitive, physical and social functioning), depressive symptoms (CES-D classification) and use of treatments for depressive symptoms (TDS). After multiple adjustment for gender and unemployment, CD4 cell count <200 per mm(3) was associated with a negative impact of fatigue on the physical functioning dimension (P = 0.002). A higher number of symptoms causing discomfort significantly predicted a higher impact of fatigue on all three dimensions (P < 0.001). This was also true for patients with DS receiving TDS when compared with those with no DS but receiving TDS. A significant decreasing linear trend (P < 0.001) of the impact of fatigue was found across the categories 'DS/TDS', 'DS/no TDS', 'no DS/TDS' and 'no DS/no TDS'. Despite limitations related to the cross-sectional nature of this study, our results suggest that routine screening and treatment for DS can reduce the impact of fatigue on the daily functioning of HIV-HCV co-infected patients and relieve the burden of their dual infection.
authors.affiliation: INSERM U669, Paris, France. laurent.michel@erx.aphp.fr
authors.forename: L
authors.initials: L
authors.lastname: Michel
authors.forename: V
authors.initials: V
authors.lastname: Villes
authors.forename: F
authors.initials: F
authors.lastname: Dabis
authors.forename: B
authors.initials: B
authors.lastname: Spire
authors.forename: M
authors.initials: M
authors.lastname: Winnock
authors.forename: M-A
authors.initials: MA
authors.lastname: Loko
authors.forename: I
authors.initials: I
authors.lastname: Poizot-Martin
authors.forename: M A
authors.initials: MA
authors.lastname: Valantin
authors.forename: P
authors.initials: P
authors.lastname: Bonnard
authors.forename: D
authors.initials: D
authors.lastname: Salmon-Céron
authors.forename: M P
authors.initials: MP
authors.lastname: Carrieri
mesh_terms: D000328:Adult; D000928:Antidepressive Agents / Q000627:therapeutic use*; D003863:Depression / Q000188:drug therapy*; D005221:Fatigue / Q000188:drug therapy*; D005260:Female; D005602:France; D015658:HIV Infections / Q000150:complications*; D019698:Hepatitis C, Chronic / Q000150:complications*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011795:Surveys and Questionnaires; D016896:Treatment Outcome
chemical_list: D000928:Antidepressive Agents